Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inflammation: IL-36 has proinflammatory effects in skin but not in joints.

Literature DB >> 25201385

Inflammation: IL-36 has proinflammatory effects in skin but not in joints.

Abstract

Given the known involvement of IL-36 in psoriasis it might be surprising that the latest mouse models show that inhibiting IL-36 signalling does not alter the course of inflammatory arthritis. Can we now add IL-36 to the list of inflammatory mediators that are not viable DMARD targets?

Entities: Disease Species

Mesh：

Substances：

Year: 2014 PMID： 25201385 DOI： 10.1038/nrrheum.2014.156

Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543

9 in total

1. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells.

Authors: Solenne Vigne; Gaby Palmer; Praxedis Martin; Céline Lamacchia; Deborah Strebel; Emiliana Rodriguez; Maria L Olleros; Dominique Vesin; Irene Garcia; Francesca Ronchi; Federica Sallusto; John E Sims; Cem Gabay
Journal: Blood Date: 2012-09-11 Impact factor: 22.113

2. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk.

Authors: Luigi Tortola; Esther Rosenwald; Brian Abel; Hal Blumberg; Matthias Schäfer; Anthony J Coyle; Jean-Christoph Renauld; Sabine Werner; Jan Kisielow; Manfred Kopf
Journal: J Clin Invest Date: 2012-10-15 Impact factor: 14.808

3. IL-36R ligands are potent regulators of dendritic and T cells.

Authors: Solenne Vigne; Gaby Palmer; Céline Lamacchia; Praxedis Martin; Dominique Talabot-Ayer; Emiliana Rodriguez; Francesca Ronchi; Federica Sallusto; Huyen Dinh; John E Sims; Cem Gabay
Journal: Blood Date: 2011-08-22 Impact factor: 22.113

4. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.

Authors: Slaheddine Marrakchi; Philippe Guigue; Blair R Renshaw; Anne Puel; Xue-Yuan Pei; Sylvie Fraitag; Jihen Zribi; Elodie Bal; Céline Cluzeau; Maya Chrabieh; Jennifer E Towne; Jason Douangpanya; Christian Pons; Sourour Mansour; Valérie Serre; Hafedh Makni; Nadia Mahfoudh; Faiza Fakhfakh; Christine Bodemer; Josué Feingold; Smail Hadj-Rabia; Michel Favre; Emmanuelle Genin; Mourad Sahbatou; Arnold Munnich; Jean-Laurent Casanova; John E Sims; Hamida Turki; Hervé Bachelez; Asma Smahi
Journal: N Engl J Med Date: 2011-08-18 Impact factor: 91.245

5. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium.

Authors: Silke Frey; Anja Derer; Maria-Elena Messbacher; Dominique L P Baeten; Serena Bugatti; Carlomaurizio Montecucco; Georg Schett; Axel J Hueber
Journal: Ann Rheum Dis Date: 2012-12-25 Impact factor: 19.103

6. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin.

Authors: Alexander M Foster; Jaymie Baliwag; Cynthia S Chen; Andrew M Guzman; Stefan W Stoll; Johann E Gudjonsson; Nicole L Ward; Andrew Johnston
Journal: J Immunol Date: 2014-05-14 Impact factor: 5.422

7. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes.

Authors: David Magne; Gaby Palmer; Jenny L Barton; Francoise Mézin; Dominique Talabot-Ayer; Sylvette Bas; Trevor Duffy; Marcus Noger; Pierre-Andre Guerne; Martin J H Nicklin; Cem Gabay
Journal: Arthritis Res Ther Date: 2006-04-28 Impact factor: 5.156

8. Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.

Authors: Anja Derer; Bettina Groetsch; Ulrike Harre; Christina Böhm; Jennifer Towne; Georg Schett; Silke Frey; Axel J Hueber
Journal: PLoS One Date: 2014-08-11 Impact factor: 3.240

9. The severity of experimental arthritis is independent of IL-36 receptor signaling.

Authors: Céline Lamacchia; Gaby Palmer; Emiliana Rodriguez; Praxedis Martin; Solenne Vigne; Christian A Seemayer; Dominique Talabot-Ayer; Jennifer E Towne; Cem Gabay
Journal: Arthritis Res Ther Date: 2013-03-01 Impact factor: 5.156

9 in total

17 in total

1. Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation.

Authors: Li Zhou; Viktor Todorovic; Steve Kakavas; Bernhard Sielaff; Limary Medina; Leyu Wang; Ramkrishna Sadhukhan; Henning Stockmann; Paul L Richardson; Enrico DiGiammarino; Chaohong Sun; Victoria Scott
Journal: J Biol Chem Date: 2017-11-27 Impact factor: 5.157

2. IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-β-Mediated Collagen Expression.

Authors: Sol Kim; Drake W Williams; Cindy Lee; Terresa Kim; Atsushi Arai; Songtao Shi; Xinmin Li; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal: J Bone Miner Res Date: 2016-10-12 Impact factor: 6.741

3. A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage.

Authors: Vu L Ngo; Hirohito Abo; Estera Maxim; Akihito Harusato; Duke Geem; Oscar Medina-Contreras; Didier Merlin; Andrew T Gewirtz; Asma Nusrat; Timothy L Denning
Journal: Proc Natl Acad Sci U S A Date: 2018-05-14 Impact factor: 11.205

4. Opposing Effects of IL-1Ra and IL-36Ra on Innate Immune Response to Pseudomonas aeruginosa Infection in C57BL/6 Mouse Corneas.

Authors: Nan Gao; Rao Me; Chenyang Dai; Berhane Seyoum; Fu-Shin X Yu
Journal: J Immunol Date: 2018-06-11 Impact factor: 5.422